Back to overview

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Publication date 2014
Author Leiser Dominic, Pochon Benoit, Blank-Liss Wieslawa, Francica Paola, Glueck Astrid Andreina, Aebersold Daniel Matthias, Zimmer Yitzhak, Medova Michaela,
Project The link between aberrant MET signaling and DNA repair pathways in liver tumor cells as a target for sensitization to DNA damaging agents
Show all

Original article (peer-reviewed)

Journal FEBS Letters
Volume (Issue) 588(5)
Page(s) 653 - 658
Title of proceedings FEBS Letters
DOI 10.1016/j.febslet.2013.12.025


The MET receptor tyrosine kinase is deregulated primarily via overexpression or point mutations in various human cancers and different strategies for MET inhibition are currently evaluated in clinical trials. We observed by Western blot analysis and by Flow cytometry that MET inhibition by different MET small molecule inhibitors surprisingly increases in a dose-dependent manner total MET levels in treated cells. Mechanistically, this inhibition-related MET accumulation was associated with reduced Tyr1003 phosphorylation and MET physical association with the CBL ubiquitin ligase with concomitant decrease in MET ubiquitination. These data may suggest careful consideration for design of anti-MET clinical protocols.